Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc by-nc-nd (c) Otero Torres, Sara et al., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/214570

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Introduction: The increased risk of severe and life -threatening toxicity in patients with dihydropyridine dehydrogenase (DPD) deficiency, under treatment with fluoropyrimidines, has been widely studied. An up-to-date overview of systematic reviews summarizing existing literature can add value by highlighting most relevant information and supports decision -making regarding treatment in DPD deficient patients. The main objective of this overview of systematic reviews is to identify published systematic reviews on the association between germline variations in the DPYD gene and fluoropyrimidine toxicity. Methods and analysis: This protocol was developed following the Preferred Reported Items for Systematic Review and Meta -analysis Protocols (PRISMA-P) checklist, and the overview of systematic reviews will be reported in accordance with the PRISMA statement. PubMed, Embase, Scopus, and the Cochrane Library will be searched from inception to 2023. Systematic reviews irrespective of study designs that analyze the association between germline variations in the DPYD and fluoropyrimidine toxicity will be considered. Methodological quality will be assessed using AMSTAR2 checklist (Measurement Tool to Assess Systematic Reviews 2). Two independent investigators will perform the study selection, quality assessment, and data collection. Discrepancies will be solved by a third investigator. Registration details: Registration number in PROSPERO: CRD42023401226. (c) 2023 Sociedad Espa & ntilde;ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Citation

Citation

OTERO TORRES, Sara, et al. DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol. Farmacia Hospitalaria. 2024. Vol. 48, num. 2, pags. 79-82. ISSN 2171-8695. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/214570

Export metadata

JSON - METS

Share record